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An artificial CO-releasing metalloprotein built by
histidine-selective metallation†
Ineˆs S. Albuquerque,a He´lia F. Jeremias,b Miguel Chaves-Ferreira,a
Dijana Matak-Vinkovic,c Omar Boutureira,c Carlos C. Roma˜ob and
Gonçalo J. L. Bernardes*ac
We report the design and synthesis of an aquacarbonyl Ru(II) dication
cis-[Ru(CO)2(H2O)4]
2+ reagent for histidine (His)-selectivemetallation of
interleukin (IL)-8 at site 33. The artificial, non-toxic interleukin (IL)-8-
RuII(CO)2 metalloprotein retained IL-8-dependent neutrophil chemo-
tactic activity and was shown to spontaneously release CO in live cells.
The chemical re-design of native protein scaﬀolds as artificial
metalloproteins through the attachment of organometallic moieties
oﬀers tantalising opportunities not only in (bio)catalysis1–5 but also
for the delivery of organometallic-based drugs.6 In one example, an
artificial metallohydrolase featuring two different metal ions, Zn(II)
and Hg(II), which are required for catalysis and structural stability,
respectively, was shown to catalyse p-nitrophenyl acetate ( pNPA)
hydrolysis with an efficiency comparable to that of human carbonic
anhydrase (CA)-II and much higher than similar synthetic
complexes.7 In another example, a bifunctional artificial strep-
tavidin metalloenzyme, displaying both an engineered carboxylate
side-chain and a docked biotinylated rhodium(III) complex, enabled
catalytic asymmetric C–H activation.8 In addition to catalysis,
artificial metalloproteins have also shown promise for the in vivo
delivery of organometallic-based drugs. For example, Pt(IV) prodrugs
have been designed to specifically bind in a non-covalent manner to
human serum albumin (HSA) as a delivery vehicle, enhancing
significantly its stability in whole human blood.9
Anchoring of a non-native organometallic moiety into a protein
template is a challenging task and it is usually achieved using dative,
covalent or supramolecular strategies.4,5 Among these, covalent
modification of cysteine (Cys) residues with complexes bearing
reactive electrophilic handles (namely prosthetics) has received
considerable attention.1–5 Cys bioconjugation with a-haloacetamide
functionalised complexes has been used to create, for example, an
artificial Diels–Alderase10 and an artificial metalloenzyme for olefin
metathesis.11 While the covalent conjugation of metal complexes
equipped with reactive handles to nucleophilic side chains on
proteins has been already demonstrated, the direct metallation of
a native or non-native pre-determined site on a protein scaffold by
creating a stable side chain–metal bond is less common. In this
context, the non-selective metallation of histidine (His), a privileged
metallophile residue, has been exploited in coordination-based
protein modification strategies12 using the nickel(Ni)(II)–His-tag
pair13 as well as in other metallation reactions with cobalt (Co)14
and ruthenium (Ru) complexes.15 Unlike these remarkable exam-
ples, His-selective metallation of proteins leading to stable, fully
functional materials is to the best of our knowledge unprecedented.
Alternatively, one could consider employing genetic encoding meth-
ods to introduce an unnatural amino acid with a designer side chain
for metal binding. This approach has been recently utilized by
Roelfes and co-workers to create an artificial metalloprotein for
catalytic asymmetric Friedel–Crafts alkylation reactions.16
We have previously described the interactions of the Ru
carbonyl complex [ fac-RuCl(k2-H2NCH2CO2)(CO)3] (CORM-3; Fig. 1A)
with proteins.17–19 X-ray crystallography showed the formation
of a di-carbonyl Ru protein complex by modification of histidine
(His)-15 in hen egg white lysozyme (HEWL) with the fragment cis-
[Ru(CO)2]
2+.17 This fragment is likely to arise from the hydrolytic
decomposition of CORM-3 in aqueous solution through a water-
gas shift reaction (Fig. S1, ESI†).19,20 In this work, we hypothesised
whether the reactivity of the cis-[Ru(CO)2]
2+ fragment would allow
for direct selective His metallation of proteins and thus provide a
robust strategy for the construction of synthetic Ru dicarbonyl
metalloproteins. We envisioned that the cis-[Ru(CO)2]
2+ could be
generated directly from an aquacarbonyl Ru(II) dication cis-
[Ru(CO)2(H2O)4]
2+ (Fig. 1A). The expected chemically defined,
artificial Ru dicarbonyl metalloproteins are interesting targets
as these have been demonstrated to carry and deliver therapeutic
active CO carriers in vivo.21
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As a protein scaﬀold we chose the CXC chemokine interleukin-8
(IL-8), which is associated with the promotion of neutrophil
chemotaxis and degranulation upon inflammatory stimuli. IL-8
activates multiple intracellular signalling pathways down-
stream of two G protein-coupled receptors (CXCR1 and CXCR2),
and over-expression of IL-8 and/or its receptors has been described
in cancer and endothelial cells, infiltrating neutrophils and
tumour-associated macrophages, demonstrating the key roles of
IL-8 as a regulatory factor within the tumour microenvironment.22
Structurally, IL-8 features two His residues, His18 and His 33,
that in solution display lower pKa values (3.7 and 4.9, respectively)
thanHis usually does (pKaB 6.0).
23–25 The unique reactivity of each
of the His residues present in IL-8 makes it an ideal scaffold to
achieve His-selective metallation with the cis-[Ru(CO)2]
2+ fragment.
We began by synthesising the aquacarbonyl Ru(II) dication
cis-[Ru(CO)2(H2O)4]
2+ complex (Fig. 1). Although our data strongly
indicate that the cis-[Ru(CO)2]
2+ fragment is generated in situ
as the result of the hydrolytic decomposition of CORM-3, we
decided to synthesise the complex aquacarbonyl Ru(II) dication
cis-[Ru(CO)2(H2O)4]
2+ (Fig. 1), which would be a more direct
source of the fragment cis-[Ru(CO)2]
2+. The synthesis and
characterization of the tosylate (OTs) salt of this complex has
been described by Merbach and co-workers.26 The reported
preparation is, however, lengthy and far from straightforward,
so we decided to prepare the cis-[Ru(CO)2]
2+ containing species
in aqueous medium, through the reaction of the readily acces-
sible [Ru(CO)2Cl2]n and Ag(OTs).
27 After removing solid AgCl,
the FTIR spectrum (ATR) of the solution showed two CO
stretching bands at 2081 and 2009 cm1. The 13C NMR spec-
trum of the residue obtained after evaporation displays a single
resonance at d 192 ppm (Fig. S3, ESI†). Spectroscopic data
are in accordance with what was previously published,26 and
indicate the presence of a single cis-[Ru(CO)2]
2+ species.
With the aquacarbonyl Ru(II) dication cis-[Ru(CO)2(H2O)4]
2+
in hand we started the metallation reaction by reacting 50
equivalents of this complex with IL-8 for 30 minutes at room
temperature in phosphate buﬀer solution (PBS) pH 7.4 (Fig. 2B).‡
The same reaction conditions were also tested using CORM-3
instead of the Ru aquacarbonyl complex. After purification by
size exclusion chromatography to remove excess of reagent,
denatured nanoESI MS† shows the presence of a major species
(480% conversion), IL-8 in complex with one cis-[Ru(CO)2]
2+
fragment (component B; Fig. 1C). In addition, minor species
corresponding to IL-8 only (component A; see also Fig. S4, ESI†
for denatured nanoESI MS of IL-8) and IL-8 in complex with
two cis-[Ru(CO)2]
2+ fragments (component C) could also be
detected. The use of additional equivalents of both reagents
and increasing the temperature and reaction time resulted in
additional labelling and/or protein loss. This result indicates
potential selective labelling of a single His residue but also
shows that, in solution, CORM-3 rapidly decomposes to form
a highly reactive cis-[Ru(CO)2]
2+ fragment that is captured by
exposed, reactive His residues on proteins.
Next, to determine the labelling site, we subjected the
IL-8-RuII(CO)2 conjugate to proteolysis and analysed the digested
fragments by nano LC-MS/MS. 19 unique peptides were identi-
fied covering 70% of the sequence. The peptide containing
amino acids 27–42 [VIESGPHCANTEIIVK] has a cis-[Ru(CO)2]
2+
modification at His33, which was further corroborated in the
MS/MS spectrum (Fig. S5, ESI†). No modification could be
found at His18, demonstrating that His33 is the primary site
of metallation. Interestingly, this result also shows that the
His–Ru bond is stable under processing/analysis conditions
similar to other His–Ru complexes.15 The stability of the pre-
sent site- and residue (His)-selective strategy opens up the
development of orthogonal double His modification protocols
for the installation of dual labels that will ensure probe homo-
geneity unlike other nonselective metallation protocols.
Having shown that it is possible to achieve selective metallation
of His33 in IL-8, we next studied whether the new artificial
chemically defined metalloproteins could spontaneously release
one CO ligand from the introduced cis-[Ru(CO)2]
2+ motif. Our
group is interested in innovative methods for the in vivo delivery of
therapeutic CO6,28 and has recently demonstrated that RuII(CO)2–
albumin complexes are able to carry and release CO in aqueous
solution, live cells and mice.21 The viability of HeLa cells in the
presence of the artificial IL-8-RuII(CO)2 metalloprotein (Fig. 2A) was
Fig. 1 His-selective metallation of IL-8 with the [Ru(CO)2]
2+ fragment.
(A) Structure of CORM-3 and the Ru complex used in this work,
cis-[Ru(CO)2(H2O)4]
2+. (B) Metallation of more reactive histidine 33 in IL-8 with
the cis-[Ru(CO)2]
2+ fragment. (C) Denatured nanoESI MS of the purified
product resulting from the reaction of IL-8 and cis-[Ru(CO)2(H2O)4]
2+. The
sample contains mainly IL-8 in complex with one cis-[Ru(CO)2]
2+ fragment
(component B) (480%). In addition, IL-8 only (component A; see also
Fig. S2 in the ESI† for denatured nanoESI MS of IL-8) and IL-8 in complex
with two cis-[Ru(CO)2]
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verified by MTT assay and confocal microscopy. Furthermore,
the selective CO fluorescent turn-on probe (COP-1)29 was used
to check for CO release from IL-8-RuII(CO)2 in aqueous buffered
(PBS) solution at physiological pH 7.4 (PBS pH 7.4). The results
reflect a robust fluorescence response of COP-1 in the presence of
an IL-8-RuII(CO)2 solution that increased in a time-dependent
manner while COP-1 alone showed very weak fluorescence
(Fig. 2B). Using this assay, we could visualize cytosolic CO
release (associated with COP-1 staining), which seems to be
intensely associated with the perinuclear region (Fig. 2C), in
accordance to what we previously reported.21 Interpreted as a
whole, these data further corroborate the benefits associated
with the use of protein scaffolds for carrying and delivering CO.
IL-8 is a chemokine produced and secreted by macrophages
and other cell-types including epithelial cells. In addition to its
role as a promoter of angiogenesis in humans,22 IL-8 acts
mainly as a chemotactic factor, by inducing migration of
neutrophils and other granulocytes towards infection sites. To
assess if IL-8 retained its chemotactic activity when conjugated
to the cis-[Ru(CO)2]
2+ motif, a neutrophil migration assay was
performed, using human neutrophils isolated from freshly col-
lected blood. Neutrophil migration induced by the artificial
metalloprotein IL-8-RuII(CO)2 was compared against that which
Fig. 2 CO release in buﬀered aqueous solution and live HeLa cells from
metallated IL-8. (A) Eﬀects of 24 and 48 h of incubation with IL-8-RuII(CO)2
on the viability of HeLa cells. Cells were incubated with MTT reagent
diluted in culture medium for 4 h, medium was removed and the pellet was
re-suspended in DMSO. After 20 min, the absorbance was measured at
540 nm (measuring in parallel at 690 nm, to remove interference from
phenol red, present in the medium). The results are shown as percentage
of control. (B) CO release measurements using COP-1, read from 497 to
558 nm, followed by excitation (lex = 488 nm). Photos were taken at 0, 5,
15, 30, 45 and 60 min after the addition of 1 mM COP-1 in PBS pH 7.4
at 37 1C. Cells were previously incubated with either IL-8 at 25 ng mL1 or
IL-8-Ru(CO)2, at 150 mM before the addition of COP-1. The results are
shown as mean fluorescence intensity (arbitrary units) normalized to the
cell-surface area. (C) Confocal microscopy images for cellular CO release
in HeLa cells treated with IL-8 (control; top panel) or IL-8-Ru(CO)2
(bottom panel), at 30 min after COP-1 addition. Cells were stained with
Hoechst 33342 (blue) and CO-release was measured by COP-1 turn-on
reaction (green). Pictures on the right represent a merge of green and blue
channels. The scale bar is 25 mm.
Fig. 3 In vitro neutrophil chemotactic activity of metallated IL-8.
(A) Representative photos of Transwell membranes of each condition
analysed in the neutrophil migration assays. The top panel includes
culture-medium controls (‘‘control’’ and ‘‘negative control’’, i.e. complete
culture medium and medium without foetal bovine serum (FBS), respec-
tively), and the bottom panel includes medium supplemented with IL-8 or
medium supplemented with IL-8-Ru(CO)2. IL-8 was used at physiological
concentration (25 ng mL1). Neutrophils were stained with Crystal Violet
and photos were taken at 40 amplification for counting. (B) Normalized
number of neutrophils that were retained in the Transwell membrane,
which did not migrate during the migration assay. Freshly isolated human
neutrophils were incubated with either complete medium (‘‘control’’),
medium without FBS (‘‘negative control’’), complete medium with IL-8
(‘‘IL-8 only’’) or complete medium with IL-8-Ru(COs)2 (‘‘IL-8-Ru(CO)2’’),
and incubated for 3 h. Bars represent mean S.E.M. of technical replicates,
obtained from two independent donors. Counts were obtained for five























































































3996 | Chem. Commun., 2015, 51, 3993--3996 This journal is©The Royal Society of Chemistry 2015
native IL-8 can induce. In the migration assay, IL-8-RuII(CO)2 was
able to decrease neutrophil retention in the Transwell membrane
at similar levels to those induced by IL-8 alone, i.e. both
unmodified and modified IL-8 increase neutrophil migration
(Fig. 3). Previous modification of IL-8 by introduction of the
natural posttranslational modification citrullination had led to a
considerable reduction in chemotactic activity.30 Importantly, our
data simultaneously demonstrate that both conjugation of IL-8 to
the Ru dicarbonyl motif and the CO released from IL-8-Ru(CO)2
does not disturb IL-8 neutrophil chemotactic activity.
In summary, we have developed a chemical His-selective
metallation method that enables the introduction of a Ru
dicarbonyl motif at His33 in IL-8. The cis-[Ru(CO)2]
2+ fragment
could be generated directly from the aquacarbonyl Ru(II) dication
cis-[Ru(CO)2(H2O)4]
2+. In addition, we were able to show that CO
can spontaneously be released from the new artificial metallo-
protein, both in aqueous solution and live cells. Importantly, the
use of IL-8 as a scaﬀold for the engineering of a new artificial
metalloprotein did not alter the protein’s activity leading to a
novel, fully functional material. In the case of IL-8 neither the
introduction of the Ru moiety nor the CO released impacted
IL-8’s neutrophil chemotactic activity. Overall we expect that the
exquisite His discrimination presented herein will establish the
basis to precisely understand the roles of diﬀerent metallation
sites in CO delivery using proteins and hopefully pave the way
towards the development of artificial metalloproteins for the safe
and controlled delivery of therapeutic CO.
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